by Sermonix Pharmaceuticals | Apr 21, 2021 | News
Preclinical effort will examine effect of lasofoxifene on unique endometrial cancer models carrying ESR1 mutations COLUMBUS, Ohio, April 21, 2021 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative...
by Sermonix Pharmaceuticals | Jan 13, 2021 | News
Garner’s pharma development expertise includes women’s health and gynecologic oncology COLUMBUS, Ohio, Jan. 07, 2021 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology...
by Sermonix Pharmaceuticals | Dec 3, 2020 | News
The poster will be made available at SABCS.org on Wednesday, Dec. 9 COLUMBUS, Ohio, Dec. 03, 2020 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision...
by Sermonix Pharmaceuticals | Dec 3, 2020 | News
The poster will be made available at SABCS.org on Wednesday, Dec. 9 COLUMBUS, Ohio, Dec. 02, 2020 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision...
by Sermonix Pharmaceuticals | Oct 13, 2020 | News
Working with Tempus to identify and enroll trial participants, study will evaluate safety of combination for treatment of women with ER+/HER2- metastatic breast cancer and an ESR1 mutation COLUMBUS, Ohio, Oct. 13, 2020 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals...
by Sermonix Pharmaceuticals | Sep 30, 2020 | News
Study of lasofoxifene versus fulvestrant in patients with metastatic breast cancer will include seven precision-medicine Exactis Network study locations COLUMBUS, Ohio, Sept. 30, 2020 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held...
Recent Comments